Fol. Biol. 2013, 59, 181-187

https://doi.org/10.14712/fb2013059050181

Serum Levels of Matrix Metalloproteinases 2 and 9 in Patients with Acute Myocardial Infarction

Jana Šímová1,2, J. Škvor3, D. Slovák2, I. Mazura2, J. Zvárová2

1Department of Anthropology and Human Genetics, Faculty of Science, Charles University in Prague, Czech Republic
2European Centre of Medical Informatics, Statistics and Epidemiology, Institute of Computer Science AS CR, v. v. i., and First Faculty of Medicine, Charles University in Prague, Czech Republic
3Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University in Prague, Czech Republic

Received May 2013
Accepted July 2013

References

1. Ducharme, A., Frantz, S., Aikawa, M., Rabkin, E., Lindsey, M., Rohde, L. E., Schoen, F. J., Kelly, R. A., Werb, Z., Libby, P., Lee, R. T. (2000) Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J. Clin. Invest. 106, 55-62. <https://doi.org/10.1172/JCI8768>
2. Fang, L., Gao, X. M., Moore, X. L., Kiriazis, H., Su, Y., Ming, Z., Lim, Y. L., Dart, A. M., Du, X. J. (2007) Differences in inflammation, MMP activation and collagen damage account for gender difference in murine cardiac rupture following myocardial infarction. J. Mol. Cell Cardiol. 43, 535-544. <https://doi.org/10.1016/j.yjmcc.2007.06.011>
3. Fang, L., Gao, X. M., Samuel, C. S., Su, Y., Lim, Y. L., Dart, A. M., Du, X. J. (2008) Higher levels of collagen and facilitated healing protect against ventricular rupture following myocardial infarction. Clin. Sci. 115, 99-106. <https://doi.org/10.1042/CS20070365>
4. Fang, L., Du, X. J., Gao, X. M., Dart, A. (2010) Activation of peripheral blood mononuclear cells and extracellular matrix and inflammatory gene profile in acute myocardial infarction. Clin. Sci. 119, 175-183. <https://doi.org/10.1042/CS20100011>
5. Hayashidani, S., Tsutsui, H., Ikeuchi, M., Shiomi, T., Matsusaka, H., Kubota, T., Imanaka-Yoshida, K., Itoh, T., Takeshita, A. (2003) Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 285, H1229-H1235. <https://doi.org/10.1152/ajpheart.00207.2003>
6. Hojo, Y., Ikeda, U., Ueno, S., Arakawa, H., Shimada, K. (2001) Expression of matrix metalloproteinases in patients with acute myocardial infarction. Jpn. Circ. J. 65, 71-75. <https://doi.org/10.1253/jcj.65.71>
7. Kaden, J. J., Dempfle, C. E., Sueselbeck, T., Brueckmann, M., Poerner, T. C., Haghi, D., Haase, K. K., Borggrefe, M. (2003) Time-dependent changes in the plasma concentration of matrix metalloproteinase 9 after acute myocardial infarction. Cardiology 99, 140-144. <https://doi.org/10.1159/000070670>
8. Kai, H., Ikeda, H., Yasukawa, H., Kai, M., Seki, Y., Kuwahara, F., Ueno, T., Sugi, K. Imaizumi, T. (1998) Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 32, 368-372. <https://doi.org/10.1016/S0735-1097(98)00250-2>
9. Kelly, D., Cockerill, G., Ng, L. L., Thompson, M., Khan, S., Samani, N. J., Squire, I. B. (2007) Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur. Heart J. 28, 711-718. <https://doi.org/10.1093/eurheartj/ehm003>
10. Lindsey, M., Wedin, K., Brown, M. D., Keller, C., Evans, A. J., Smolen, J., Burns, A. R., Rosse, R. D., Michael, L., Entman, N. (2001) Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 103, 2181-2187. <https://doi.org/10.1161/01.CIR.103.17.2181>
11. Matsunaga, T., Abe, N., Kameda, K., Hagii, J., Fujita, N., Onodera, H., Kamata, T., Ishizaka, H., Hanada, H., Osanai, T., Okumura, K. (2005) Circulating level of gelatinase activity predicts ventricular remodeling in patients with acute myocardial infarction. Int. J. Cardiol. 105, 203-208. <https://doi.org/10.1016/j.ijcard.2005.01.011>
12. Morrison, C. J., Butler, G. S., Rodríguez, D., Overall, C. M. (2009) Matrix metalloproteinase proteomics: substrates, targets, and therapy. Curr. Opin. Cell Biol. 21, 645-653. <https://doi.org/10.1016/j.ceb.2009.06.006>
13. Murphy, G., Nagase, H. (2008) Progress in matrix metalloproteinase research. Mol. Aspects Med. 29, 290-308. <https://doi.org/10.1016/j.mam.2008.05.002>
14. Page-McCaw, A., Ewald, A. J., Werb, Z. (2007) Matrix metalloproteinases and the regulation of tissue remodeling. Nat. Rev. Mol. Cell Biol. 8, 221-33. <https://doi.org/10.1038/nrm2125>
15. Raffetto, J. D., Khalil, R. A. (2008) Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem. Pharmacol. 75, 346-59. <https://doi.org/10.1016/j.bcp.2007.07.004>
16. Sekhon, B. S. (2010) Matrix metalloproteinases – an overview. Res. Rep. Biol. 1, 1-20.
17. Šímová, J., Škvor, J., Reissigová, J., Dudra, J., Lindner, J., Čapek, P., Zvárová, J. (2013) Serum levels of matrix metalloproteinase-2 and -9 and TGFBR2 gene screening in patients with ascending aortic dilatation. Folia Biol. (Praha) 4, 154-161.
18. Sundstrom, J., Evans, J. C., Benjamin, E. J., Levy, D., Larson, M. G., Sawyer, D. B., Siwik, D. A., Colucci, W. S., Sutherland, P., Wilson, P. W., Vasan, R. S. (2004) Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 109, 2850-2856. <https://doi.org/10.1161/01.CIR.0000129318.79570.84>
19. Tayebjee, M. H., Lip, G. Y., Blann, A. D., MacFadyen, R. J. (2005) Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. Thromb. Res. 115, 205-210. <https://doi.org/10.1016/j.thromres.2004.08.023>
20. Valenta, Z., Mazura, I., Kolar, M., Grunfeldova, H., Feglarova, P., Peleska, J., Tomecková, M., Kalina, J., Slovak, D., Zvarova, J. (2012) Determinants of excess genetic risk of acute myocardial infarction – a matched case-control study. EJBI 8, 34-43. <https://doi.org/10.24105/ejbi.2012.08.1.6>
21. Wagner, D. R., Delagardelle, C., Ernens, I., Rouy, D., Vaillant, M., Beissel, J. (2006) Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J. Card. Fail. 12, 66-72. <https://doi.org/10.1016/j.cardfail.2005.08.002>
22. Webb, C. S., Bonnema, D. D., Ahmed, S. H., Leonardi, A. H., McClure, C. D., Clark, L. L., Stroud, R. E., Corn, W. C., Finklea, L., Zile, M. R., Spinale, F. G. (2006) Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation 114, 1020-1027. <https://doi.org/10.1161/CIRCULATIONAHA.105.600353>
23. Yong, V. W., Agrawal, S. M., Stirling, D. (2007) Targeting MMPs in acute and chronic neurological conditions. Neurotherapeutics 4, 580-589. <https://doi.org/10.1016/j.nurt.2007.07.005>
24. Zhang, X., Ying, H. S., Scott, A. L. (2009) Thoracic aortic dissection: Are matrix metalloproteinases involved? Vascular 17, 147-157. <https://doi.org/10.2310/6670.2008.00087>
front cover

ISSN 0015-5500 (Print) ISSN 2533-7602 (Online)

Open access journal

Submissions

Archive